Niacin revisited: Clinical observations on an important but underutilized drug

Keyphrases

• Clinical Observation 100%
• Underutilization 100%
• Niacin 100%
• Hepatitis 27%
• Low-density Lipoprotein Cholesterol (LDL-C) 22%
• Sustained Release 16%
• High-density Lipoprotein Cholesterol (HDL-C) 11%
• Sustained-release Preparations 11%
• Pharmacist 5%
• Pharmacy 5%
• Cholesterol 5%
• Hyperglycemia 5%
• Retrospective Analysis 5%
• Type 1 Diabetes Mellitus (T1DM) 5%
• Dyslipidemia 5%
• Lipoproteins 5%
• Patient Charts 5%
• Group 11 5%
• Heart Transplant Recipients 5%
• Drug Combination 5%
• Transplant Patients 5%
• Identical Twins 5%
• Patient-physician 5%
• Immediate Release 5%
• Effective Compounds 5%
• Physician Competencies 5%
• Nonprescription Drugs 5%
• Medical Supervision 5%
• Adequate Dose 5%
• Nontransplant 5%
• Familial Predisposition 5%
• Patient Motivation 5%
• Non-transplant Patients 5%
• Lipid Disorders 5%
• Lipid-modifying Drugs 5%
• Outpatient Referral 5%
• Lovastatin 5%

Nursing and Health Professions

• Nicotinic Acid 100%
• Clinical Observation 100%
• Side Effect 16%
• Sustained Drug Release 16%
• Lipoprotein 16%
• Hospital 11%
• Transplantation 11%
• Sustained Release Preparation 11%
• Disease 5%
• Patient Referral 5%
• Outpatient 5%
• Hyperglycemia 5%
• Diabetes Mellitus 5%
• Dyslipidemia 5%
• High Density Lipoprotein Cholesterol 5%
• Cholesterol Blood Level 5%
• Low Density Lipoprotein Cholesterol 5%
• High Density Lipoprotein Cholesterol Level 5%
• Atherosclerosis 5%
• Disease Predisposition 5%
• Very Low Density Lipoprotein 5%
• Non Prescription Drug 5%
• Heart Graft 5%
• Combination Drug 5%
• Mevinolin 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Nicotinic Acid 100%
• Sustained Release 27%
• Side Effect 16%
• Lipoprotein 16%
• High Density Lipoprotein Cholesterol 11%
• Diabetes Mellitus 5%
• Disease 5%
• Combination Drug 5%
• Hyperglycemia 5%
• Dyslipidemia 5%
• Low Density Lipoprotein Cholesterol 5%
• Non Prescription Drug 5%
• Disease Predisposition 5%
• Atherosclerosis 5%
• Very Low Density Lipoprotein 5%
• Mevinolin 5%
• Lipid Modifying Drug 5%